ATRX (Adhera Therapeutics) Days Sales Outstanding: (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATRX Adhera Therapeutics Inc ATRX
12 GF Score
Price $0.00
View Full Analysis

What is Adhera Therapeutics Days Sales Outstanding?

Adhera Therapeutics's average Accounts Receivable for the three months ended in Sep. 2023 was $0.00 Mil. Adhera Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil.

The historical rank and industry rank for Adhera Therapeutics's Days Sales Outstanding or its related term are showing as below:

ATRX's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 69.01
* Ranked among companies with meaningful Days Sales Outstanding only.

Adhera Therapeutics's Days Sales Outstanding stayed the same from Sep. 2022 () to Sep. 2023 ().

Adhera Therapeutics  (OTCPK:ATRX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Adhera Therapeutics Days Sales Outstanding Related Terms

Adhera Therapeutics Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for Adhera Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adhera Therapeutics Days Sales Outstanding Chart

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 231.35 69.94 - - -

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ATRX vs PKBO, ARDS, NYMXF: Days Sales Outstanding Comparison

For the Biotechnology subindustry, Adhera Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adhera Therapeutics Days Sales Outstanding vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Adhera Therapeutics's Days Sales Outstanding falls into.


ATRX
12GF Score
Adhera Therapeutics Inc ATRX
Days Sales Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adhera Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Adhera Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

Days Sales Outstanding (A: Dec. 2022 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2021 ) + Accounts Receivable (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )*Days in Period
=( ( + ) / 1 ) / 0*365
=0 / 0*365
=N/A

Adhera Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

Days Sales Outstanding (Q: Sep. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2023 ) + Accounts Receivable (A: Sep. 2023 )) / count ) / Revenue (A: Sep. 2023 )*Days in Period
=( ( + ) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adhera Therapeutics Business Description

Address 8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing advanced drug candidates through accelerated pathways. The company's pipeline includes MLR-1019 for Parkinson's disease and MLR-1023 for diabetes, both licensed from the Melior Discovery group. MLR-1019 (armesocarb) is a drug candidate targeting both movement and non-movement symptoms of Parkinson's disease, while MLR-1023 (tolimidone) is being developed for Type 1 diabetes and has undergone Phase 2a and 2b studies in Type 2 diabetes patients. It also explores additional drug development opportunities and maintains legacy assets such as CEQ508, an oral RNA therapy candidate for polyps associated with Familial Adenomatous Polyposis (FAP).
12GF Score

Get the complete analysis for ATRX

Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price